Ligand Pharmaceuticals Incorporated (LGND)vsBeiGene, Ltd. (ONC)
LGND
Ligand Pharmaceuticals Incorporated
$300.79
+3.00%
HEALTHCARE · Cap: $5.76B
ONC
BeiGene, Ltd.
$313.77
-0.71%
HEALTHCARE · Cap: $34.29B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 1991% more annual revenue ($5.74B vs $274.48M). LGND leads profitability with a 55.9% profit margin vs 8.9%. LGND trades at a lower P/E of 37.4x. LGND earns a higher WallStSmart Score of 67/100 (B-).
LGND
Strong Buy67
out of 100
Grade: B-
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-14.8%
Fair Value
$161.95
Current Price
$300.79
$138.84 premium
Margin of Safety
+81.0%
Fair Value
$1847.00
Current Price
$313.77
$1533.23 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 56 of every $100 in revenue as profit
Strong operational efficiency at 33.6%
Earnings expanding 103.2% YoY
Revenue surging 35.5% year-over-year
Earnings expanding 16971.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LGND
The strongest argument for LGND centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 55.9% and operating margin at 33.6%. Revenue growth of 14.1% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.
Bear Case : LGND
The primary concerns for LGND are PEG Ratio, P/E Ratio.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.
Key Dynamics to Monitor
LGND profiles as a mature stock while ONC is a hypergrowth play — different risk/reward profiles.
LGND carries more volatility with a beta of 0.98 — expect wider price swings.
ONC is growing revenue faster at 35.5% — sustainability is the question.
ONC generates stronger free cash flow (161M), providing more financial flexibility.
Bottom Line
LGND scores higher overall (67/100 vs 54/100), backed by strong 55.9% margins and 14.1% revenue growth. ONC offers better value entry with a 81.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ligand Pharmaceuticals Incorporated
HEALTHCARE · BIOTECHNOLOGY · USA
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?